Theratechnologies Inc T.TH

No questions on cancer

[SPCEO1]

Perhaps the most remarkable thing is that the AACR data created zero excitement in the analyst community. How is that possible? You have an exciting cancer drug that just got fast tracked in the pre-clinical stage and has pretty fascinating data and no analyst wants to ask a question about that??? Hard to fathom.

[Bucknelly21]

Thera never disappoints do they? They manage to crush every rise in the sp with poor everything on ir front 

[Sqidmandon]

I have the answer Rusty....its because you have a CFO and IR person with ZERO gravitas....Paul needs to replace them immediately...this is insane - I've never experienced anything like this before....

[SABBOBCAT]

I would be happy top throw my hat in the ring for on the IR front. CFA/MBA with 6 years in the canadian IIROC channel (Sales,trading, portfolio managementnt), 2 years of Business development. and now I am currently working in Finance for a late stage startup that just completed a raise. The only reason I would think of leaving current role and doing IR for thera is because the size of the NASH and

[PinnacleX]

you are starring to get it, only took 2 years lol

[qwerty22]

I think there are interesting questions to ask based on the AACR data, even the first patients interaction with the media raises questions. I'd want to know how melanoma might fit into the program given it's not include in the Ph1 atm. Maybe the Q&A issue was technical.